SIG.AX Sigma Healthcare (ASX) pre-market 26 Feb 2026: Earnings set price tone
SIG.AX stock opens pre-market at A$3.00 as Sigma Healthcare (ASX) prepares to publish FY25 results on 26 Feb 2026. Investors will watch revenue growth, margin trends and cash flow after reported 2025 revenue of A$6.00 billion and earnings of A$529.91 million. Early trading shows volume near 12.89M and daily range A$2.96–A$3.03, so guidance and cash conversion details should drive intraday moves and medium-term positioning.
SIG.AX stock: Earnings snapshot and FY25 context
Sigma reported FY25 revenue up 82.18% to A$6.00 billion while net earnings fell 2.05% to A$529.91 million. We expect commentary on gross margins, franchise rollouts and logistics contracts to explain the revenue jump and the modest earnings decline. Market reaction will hinge on management guidance for FY26 same-store sales and dose administration aid growth, which directly link to short-term revenue visibility.
SIG.AX stock: Valuation and key financial metrics
At A$3.00 the stock trades with EPS A$0.05 and a reported PE of 60.00, and a price-to-book near 5.63. Current ratio sits at 1.59, and operating cash flow per share is negative at -0.20, signalling working capital pressure despite strong sales growth. Investors should weigh the rich PB and PE against revenue momentum and Sigma’s asset-light distribution model.
SIG.AX stock: Meyka AI grade and model forecast
Meyka AI rates SIG.AX with a score out of 100: 64.64 (Grade B, Suggestion HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month price of A$3.86, implying an upside of +28.67% from A$3.00. Forecasts are model-based projections and not guarantees.
SIG.AX stock: Technicals and trading levels to watch
Technicals show neutral momentum: RSI 47.64, ADX 18.98, ATR A$0.06, and Bollinger middle band A$3.06. Immediate support is near A$2.96 and resistance near A$3.28 year high. Volume today is 12.89M versus average 15.28M, so follow volume spikes for conviction. Short-term traders should monitor MFI at 12.57 (oversold) and MACD histogram for any shift in intraday trend.
SIG.AX stock: Sector context, risks and opportunities
Sigma sits in the Healthcare – Medical Distribution sector where average PB is 3.80; SIG’s PB of 5.63 is a premium to peers. Opportunities include pharmacy franchising scale, logistics contracts, and aged-care dose services that could boost margins. Key risks are thin gross margins (gross margin TTM 6.83%), negative operating cash flow, and sensitivity to supplier terms and government pharmacy policy.
SIG.AX stock: Near-term catalysts and what to watch in the report
Focus items in the FY25 report: FY26 guidance for same-store sales, cash conversion cycle changes, gross margin drivers, and capital allocation including the A$0.013 dividend per share history. Earnings call commentary on contract logistics wins or pharmacy network expansion will be the primary price catalysts in pre-market and opening trade.
Final Thoughts
SIG.AX stock opens pre-market at A$3.00 with a mix of strong top-line growth and working-capital stress on the balance sheet. The FY25 numbers show revenue strength at A$6.00 billion but flagging cash flow metrics, negative operating cash flow per share -0.20, and a high PB of 5.63. Our model view is balanced: Meyka AI’s forecast model projects a 12-month A$3.86 target, an implied +28.67% upside from the current price. That projection rests on Sigma converting revenue growth into positive operating cash flow and stabilising margins. If management provides clear FY26 guidance and cash conversion improvement, the stock could re-rate toward the forecast. Conversely, weaker guidance or continued cash flow weakness would pressure the multiple from current PE 60.00. Investors should treat the Meyka forecast as a model-based projection, not a guarantee, and watch guidance, cash conversion and contract wins as the key drivers for the next 12 months.
FAQs
What key numbers move SIG.AX stock after the FY25 report?
Investors will focus on guidance for FY26 same-store sales, gross margin trends, and operating cash flow. For SIG.AX stock, a turnaround in operating cash flow per share from -0.20 toward positive territory matters most for re-rating.
How does Meyka AI view SIG.AX stock valuation?
Meyka AI assigns SIG.AX a grade B (64.64/100) with a HOLD suggestion, noting a premium PB of 5.63 and PE 60.00. The grade weighs sector, growth and key metrics against earnings quality.
What is the 12-month price forecast for SIG.AX stock?
Meyka AI’s forecast model projects a 12-month price of A$3.86, implying +28.67% upside from A$3.00 today. Forecasts are model outputs and are not guarantees.
What are the main risks to SIG.AX stock in the near term?
Near-term risks include continued negative operating cash flow, margin pressure, and adverse policy changes for pharmacies. For SIG.AX stock, any guidance that widens the cash conversion gap will likely trigger downside.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.